Search Results

Phoenix PharmaLabs, Inc. today announced that in vivo studies demonstrated that the company’s lead compound, PPL-138, reduced symptoms of PTSD and decreased alcohol consumption in a rat model of PTSD/AUD (alcohol abuse disorder).

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.

Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing potent, non-addictive treatments for pain and addiction, today announced the receipt of an $8.7 million grant from the National Institute on Drug Abuse (NIDA).

According to a study published in Nature Communications, research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix, shows how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions, called enhancers, can lead to Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a rare, lethal, genetic lung disease which causes respiratory failure in newborns and infants.

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.